Crystal commemorative recognizing a collaboration involving Virginia Commonwealth University’s Medicine for All Institute.
(20AJH069)
Crystal commemorative recognizing a collaboration involving Virginia Commonwealth University’s Medicine for All Institute.
(20AJH069)Crystal commemorative celebrating a development and commercialization agreement between Click Therapeutics and pharmaceutical firm Boehringer Ingelheim. The partnership centers on a mobile prescription app providing digital treatment for patients with schizophrenia.
(21AKL599)Lucite embedment with drug vial commemorating a study of a treatment for solid tumor cancer.
(21ADH006)Custom crystal commemorative celebrating the launch of Wynzora Cream, a topical treatment for plaque psoriasis that received approval from the FDA (Food and Drug Administration) in 2020. The product launch resulted from a collaboration agreement between Denmark-based MC2 Therapeutics, and EPI Health, a specialty pharmaceutical firm headquartered in Charleston, South Carolina.
(21ADH022)Custom crystal celebrating the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA). The application, related to Impel NeuroPharma’s migraine treatment INP104, was supported by a Phase 3, open-label STOP-301 Trial.
(20ALJ356)Crystal tombstone commemorating an exclusive licensing agreement between Ovid Therapuetics and Angelini Pharma. The agreement centers on the development, manufacturing, and commercialization of a potential treatment for Angelman syndrome.
(20AJH130)Custom crystal commemorative, incorporating a periodic table theme, marking a licensing and commercialization agreement for a cancer drug developed by Rockville, Maryland-based biotech firm GlycoMimetics. The agreement applies to mainland China, Hong Kong, Taiwan, and Macau.
(20ALJ071)Custom crystal deal toy commemorating the acquisition of Canada’s Dalton Pharma Services by Japanese pharmaceutical firm Seikagaku Corporation.
(20AMF085)
